In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 301 to 350 of 388

TitleTypeExpected publication date
Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [ID6739]Technology appraisal guidanceTBC
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6454]Technology appraisal guidanceTBC
School-based interventions: physical and mental health and wellbeing promotionQuality standardTBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]Technology appraisal guidanceTBC
Secukinumab for treating giant cell arteritis in people 50 years and over [ID6563]Technology appraisal guidanceTBC
Seladelpar for previously treated primary biliary cholangitis [ID6429]Technology appraisal guidanceTBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]Technology appraisal guidanceTBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]Technology appraisal guidanceTBC
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]Technology appraisal guidanceTBC
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]Technology appraisal guidance
Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]Technology appraisal guidanceTBC
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]Technology appraisal guidanceTBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]Technology appraisal guidance
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]Highly specialised technology
Severe and enduring mental illness guidance reviewNICE guidelineTBC
Sipavibart for preventing COVID 19 [ID6282]Technology appraisal guidanceTBC
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]Technology appraisal guidanceTBC
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]Technology appraisal guidanceTBC
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]Technology appraisal guidanceTBC
Software for electroencephalogram (EEG) interpretation to support diagnosing epilepsyHealth technology evaluation
Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]Technology appraisal guidanceTBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]Technology appraisal guidanceTBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over [TSID12091]Technology appraisal guidanceTBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [TSID10632]Technology appraisal guidanceTBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]Technology appraisal guidanceTBC
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)Medical technologies guidanceTBC
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]Technology appraisal guidance
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]Technology appraisal guidanceTBC
Subcutaneous spesolimab 1 ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over [ID6216]Technology appraisal guidanceTBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]Technology appraisal guidanceTBC
Surgical mesh for treatment of non-primary ventral herniasHealthTech guidanceTBC
Surgical mesh for treatment of primary ventral herniasHealth technology evaluation
Surgical vessel sealing systems (MT798)Medical technologies guidanceTBC
Suspected cancer updateQuality standard
Suspected Cancer: recognition and referral (update)NICE guideline
Suspected sepsis in pregnancy: recognition, diagnosis and early managementNICE guideline
Suspected sepsis in under 16s: recognition, diagnosis and early managementNICE guideline
Suspected sepsis: recognition, diagnosis and early managementNICE guidelineTBC
Suspected sepsis: recognition, diagnosis and early management - procalcitonin testingNICE guideline
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]Technology appraisal guidance
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]Technology appraisal guidance
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]Technology appraisal guidanceTBC
Tarlatamab for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]Technology appraisal guidance
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women [ID1401]Technology appraisal guidanceTBC
Technologies for the rapid diagnosis of endometriosisHealth technology evaluation
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]Technology appraisal guidanceTBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]Technology appraisal guidance
Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]Technology appraisal guidanceTBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]Technology appraisal guidance
Third molars (impacted) - prophylactic removal [ID898]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All